Test IMC-002 for advanced solid tumors after standard treatment fails
Part of Cancer clinical trials.
This Phase 1 study tests IMC-002 in people with advanced cancers that did not respond to standard therapy. It may help by trying a new immune-targeting drug approach when other options have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your legal guardian) can sign the study consent form
- You’re an adult (19 years or older) with an advanced solid tumor or one of these specific cancers
- Your cancer has spread or is locally advanced, and you’ve already tried at least one standard cancer treatment (with some cohort-specific rules)
- You can provide a stored tumor sample or agree to a fresh biopsy
- You have at least one measurable tumor spot on scans, and you’re well enough to do study activities (ECOG 0–1) for about 3+ months of expected survival
- You can meet safety needs: adequate blood counts/organ function, avoid pregnancy, and use effective birth control
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called IMC-001 for people whose cancer has spread or is locally advanced and has a high number of genetic mutations (TMB-H). The drug aims to help the immune system fight cancer.
This trial tests a new drug, IMGS-001, in people with advanced solid tumors that have grown back or not responded to standard treatments. It aims to find a safe dose and see if it helps shrink tumors.
This early-phase trial tests NB002, a new immune-targeting medicine, to find safe doses and see how well it can treat advanced or metastatic solid cancers that have not responded to standard treatments. It may help by strengthening the immune system’s ability to fight the tumor.
This trial tests a new drug (IM-1021) for people with advanced cancers like lymphoma or solid tumors who have run out of standard options. The drug targets a protein called ROR1, which is found on some cancer cells, and may help shrink tumors or slow their growth.
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
This trial tests a new combination treatment (HC010) for people with advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
Hear when a new Advanced Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.